Small molecule drug pipelines remain strong, but large molecule therapeutics are gaining momentum among biotechnology and pharmaceutical companies.  This white paper demonstrates how Nerac’s novel analytics can help overcome information paralysis created by constantly changing, overwhelmingly complex and voluminous data to help companies to make timely, profitable decisions.  

The white paper uses a case study that the authors constructed to measure large and small molecule drug pipeline trends among the pharmaceutical companies Pfizer, AstraZeneca, and Sanofi-Adventis, and the biotechnology companies Amgen, Genentech, and Genzyme. The objective was to independently analyze data from patent and non-patent sources, to determine common and uncommon conclusions about small and large molecule drug development, and to illustrate novel macro-analysis and visualization techniques to effectively analyze complex data.  

Key Findings:  

• While non-patent data indicates pharmaceutical companies are moving aggressively into large molecule drug development, patent data suggests a more measured approach.
• The case study biotechnology companies lead large molecule development, but the pharmaceutical companies are strong contenders.
• The biotechnology companies were more aggressive filing patent applications for small molecule therapeutics than pharmaceutical companies were for large molecule therapeutics, though the pharmas continue to dominate small molecule development. 
• Both small and large molecule therapeutics will find future applications in inflammation and cancer therapies.
• Small molecule drugs will continue to dominate central nervous system and infectious disease treatments.
• Based on market value projections, small molecule drugs will continue to dominate the market for the foreseeable future.